About us
Company highlights
Pivotal program
Clinical-stage pipeline
Broad technology base with modular programing approach
Manufacturing process
Our purpose
Autolus strives to develop best-in-class therapies that offer life-changing benefits for patients with cancer and autoimmune diseases
Learn more
Our history
Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities and capital required to manufacture, develop and commercialise its programmed T cell product candidates.
Read more
Leadership
Our team includes pioneers in T Cell therapies and leaders in cancer immunotherapies and autoimmune diseases who are committed to the development and delivery of novel medicines that offer life-changing benefits for people with cancer and autoimmune diseases
Learn more
Our partners
Autolus collaborates with leading academic institutions and industry partners to develop and deliver immunotherapies to patients
Learn more
Culture and values
Our team is pushing the boundaries of cancer therapy to deliver potential life-changing treatments to patients. Our employees enjoy a flexible, diverse, and dynamic working environment which actively promotes creativity, leadership and teamwork.
Find out more